Prime Medicine, Inc.
- Last sale
- Nov 12, 2026 · -9.66%
- Market cap
- $705.86M
- 181.92M shares
- Filings
- 306
Q3 2026+55.3% FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026derivedN/M FY25 yoy
Q3 2026N/M FY25 yoy
Q3 2026−65.5% FY25 yoy
- $705.86M
- —
- 152.4×
- 83.7×
- -23.67%
- —
FY2025 figures · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2025-12-31 | $4,632,000 | reported | |
| FY 2024 | 2024-12-31 | $2,983,000 | reported | |
| FY 2023 | 2023-12-31 | $0 | reported | |
| FY 2022 | 2022-12-31 | $0 | reported | |
| FY 2021 | 2021-12-31 | $0 | reported | |
| FY 2020 | 2020-12-31 | $5,210,000 | reported |
Biological products, except diagnostic substances
Prime Medicine, Inc. is the 68th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
FATEFate Therapeutics Inc$6.6M51.2%2,051.1%$161.7MDBVTDBV Technologies S.A.$5.6M35.8%2,607.3%$3.6BZEOXZeo ScientifiX, Inc.$5.2M12.5%106.2%$10.7M
PRMEPrime Medicine, Inc. (this company)$4.6M55.3%4,342.4%$705.9M
OCGNOcugen, Inc.$4.4M8.8%1,537.4%$296.3MCGONCG Oncology, Inc.$4.0M254.7%3,985.0%$6.8BCRSPCRISPR Therapeutics AG$3.5M90.6%16,569.8%$4.1BSRZNSurrozen, Inc.$3.5M67.4%6,960.8%$605.8MDYAIDyadic International Inc$3.1M11.6%238.3%$13.3MPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Prime Medicine, Inc. · CIK 1894562 · Engraved from SEC EDGAR